Crucifixion (van Dyck) Crucifixion (van Dyck) The Crucifixion is an oil on canvas painting by Anthony van Dyck, produced around 1630. It is 2.51 m high. It was originally commissioned as the high altar-piece in the convent of the Récollets in Lille during van Dyck's second Antwerp period, between his return from Italy in 1627 and his departure for London in 1632. It returned to a theme he had already painted around 1617-19 during his first Antwerp period, when he was still a studio-assistant to Rubens - this was "Crucifixion with the Virgin Mary, St John and St Mary Magdalene", sold to Rubens
Christopher H. van Dyck brain. Studies of this ligand in early Alzheimer’s Disease patients have shown a loss of synapses from the perforant path, the connections between the entorhinal cortex and hippocampal formation needed for memory consolidation. van Dyck and the Yale ADRU have tested potential Alzheimer’s therapeutics for over 20 years. They have contributed to the successful development of memantine now in use for the treatment of mid-late stage Alzheimer’s Disease, and assess potential new therapeutic strategies, e.g. antibodies that reduce amyloid pathology such as Crenezumab, and based on the work of Dr. Stephen Strittmatter, an inhibitor of fyn. Dr. van Dyck serves